Sichenzia Ross Friedman Ference LLP Advises Amarantus on $5M PIPE Investment from Discover Growth Fund
New York, NY – April 29, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and orphan diseases, on a $5 million investment from Discover Growth Fund.
Pursuant to the transaction’s Stock Purchase Agreement, Amarantus issued 1,087 shares of designated Series G Preferred stock at a fixed price of $0.06 per share for gross proceeds of $5,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- SRF是第21届年度全球投资会议的金牌赞助商 –9月8日至10日在纽约举行 - September 6, 2019
- Sichenzia Ross Ference LLP代表FINRA成员公司进行200万美元私募 - August 28, 2019
- Sichenzia Ross Ference LLP代表Aegis Capital以450万美元公开发售Avinger，Inc。普通股 - August 26, 2019